Relationship between antibodies and clinical manifestations in systemic lupus erythematosus
PDF
Cite
Share
Request
Original Article
P: 66-73
August 2022

Relationship between antibodies and clinical manifestations in systemic lupus erythematosus

J Turk Soc Rheumatol 2022;14(2):66-73
1. Sağlık Bilimleri Üniversitesi, Dışkapı Yıldırım Beyazıt Eğitim ve Araştırma Hastanesi, Dahiliye Kliniği, Romatoloji Bölümü, Ankara, Türkiye
2. Gazi Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Romatoloji Bilim Dalı, Ankara, Türkiye
No information available.
No information available
Received Date: 28.02.2022
Accepted Date: 30.05.2022
Publish Date: 29.08.2022
PDF
Cite
Share
Request

ABSTRACT

Objective:

To investigate the role between antibodies to extractable nuclear antigens (ENA) and clinical manifestations in a cohort of systemic lupus erythematosus (SLE) patients.

Methods:

The study included 187 adult patients with a diagnosis of SLE. Patients fulfilled the 2012 classification criteria for SLE. Full medical history, general examination, and laboratory investigations were recorded. Analyses of the autoantibodies [antinuclear antibody, anti-dsDNA, anti-Ro/SSA, anti-La/SSB, anti-Sm and anti-ribonucleoproteins (RNP)] in the serum of the patients at diagnosis were also undertaken by the routine clinical immunology laboratory at University Hospital.

Results:

The median age was 38 years, and 176 (94.1%) patients were women. Median disease duration was 120 months. Median levels of serum anti-dsDNA, complement 3 and 4 were found 211,7 IU/μL,78 mg/dL and 12,3 mg/dL. The most frequent clinical manifestation of these patients was musculoskeletal disorders (60.4%) the others were mucocutanous disorders, respectively (57.8%), nephritis (37.4%), haematological (18.7%), neurological disorders (12.3%). Anti-Sm, anti-RNP, anti-Ro and anti-La positivity were found in 15%, 24%, 26.7% and 11,8% of SLE cases. Multivariable analysis revealed that discoid rash was independent predictors of anti-Sm positivity; Raynaud phenomenon and oral ulcer were independent predictors of anti-RNP positivity; alopecia, lupus pneumonia and pericarditis were independent predictors of anti-Ro positivity and pleuritis was independent predictors of anti-La positivity.

Conclusion:

Presence of antibodies against ENAs may predict findings that may occur in the follow-up in patients with SLE and It may be useful for follow-up.

References

1Wallace DJ, Hahn B. Dubois’ lupus erythematosus: Lippincott Williams & Wilkins; 2007.
2Fredi M, Cavazzana I, Quinzanini M, et al. Rare autoantibodies to cellular antigens in systemic lupus erythematosus. Lupus 2014;23:672-7.
3Bai Y, Tong Y, Liu Y, Hu H. Self-dsDNA in the pathogenesis of systemic lupus erythematosus. Clin Exp Immunol 2018;191:1-10.
4Aringer M. EULAR/ACR classification criteria for SLE. Seminars in arthritis and rheumatism 2019;49:S14-s7. Epub 2019/11/30.
5Agarwal S, Harper J, Kiely P. Concentration of antibodies to extractable nuclear antigens and disease activity in systemic lupus erythematosus. Lupus 2009;18:407-12.
6Bentow C, Swart A, Wu J, et al. Clinical performance evaluation of a novel rapid response chemiluminescent immunoassay for the detection of autoantibodies to extractable nuclear antigens. Clin Chim Acta 2013;424:141-7.
7Davis JM, Moder KG, Homburger HA, Ytterberg SR. Clinical features of 39 patients with antibodies to extractable nuclear antigens despite negative antinuclear antibodies: evidence for autoimmunity including neurologic and connective tissue diseases. Medicine (Baltimore) 2005;84:208-17.
8Schur PH. Laboratory evaluation of patients with systemic lupus erythematosus.  Systemic lupus erythematosus: Elsevier; 2011. p. 629-53.
9Colglazier CL, Sutej PG. Laboratory testing in the rheumatic diseases: a practical review. South Med J 2005;98:185-91.
10Migliorini P, Baldini C, Rocchi V, Bombardieri S. Anti-Sm and anti-RNP antibodies. Autoimmunity 2005;38:47-54.
11Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
12Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526-33.
13Vlachoyiannopoulos P, Tzavara V, Dafni U, Spanos E, Moutsopoulos H. Clinical features and evolution of antinuclear antibody positive individuals in a rheumatology outpatient clinic. J Rheumatol 1998;25:886-91.
14Satoh M, Yamagata H, Watanabe F, et al. Development of anti-Sm and anti-DNA antibodies followed by clinical manifestation of systemic lupus erythematosus in an elderly woman with long-standing Sjögren’s syndrome. Lupus 1995;4:63-5.
15Gaither K, Fox O, Yamagata H, Mamula M, Reichlin M, Harley J. Implications of anti-Ro/Sjögren’s syndrome A antigen autoantibody in normal sera for autoimmunity. J Clin Invest 1987;79:841-6.
16Zarmbinski MA, Messner RP, Mandel J. Anti-dsDNA antibodies in laboratory workers handling blood from patients with systemic lupus erythematosus. J Rheumatol 1992;19:1380-4.
17Li Wg, Ye Zz, Yin Zh, Zhang K. Clinical and immunological characteristics in 552 systemic lupus erythematosus patients in a southern province of China. Int J Rheum Dis 2017;20:68-75.
18Hoffman I, Peene I, Meheus L, et al. Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann Rheum Dis 2004;63:1155-8.
19Ter Borg EJ, Groen H, Horst G, Limburg PC, Wouda AA, Kallenberg CG, editors. Clinical associations of antiribonucleoprotein antibodies in patients with systemic lupus erythematosus. Semin Arthritis Rheum 1990;20:164-73.
20Alba P, Bento L, Cuadrado M, et al. Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann Rheum Dis 2003;62:556-60.
21Ravirajan C, Rowse L, MacGowan J, Isenberg D. An analysis of clinical disease activity and nephritis-associated serum autoantibody profiles in patients with systemic lupus erythematosus: a cross-sectional study. Rheumatology (Oxford) 2001;40:1405-12.
22Wang Y, Luo P, Guo T, Zou L, Shi J, Chen P. Study on the correlation between anti-ribosomal P protein antibody and systemic lupus erythematosus. Medicine (Baltimore) 2020;99: e20192.
23Franceschini F, Calzavara-Pinton P, Quinzanini M, et al. Chilblain lupus erythematosus is associated with antibodies to SSA/Ro. Lupus 1999;8:215-9.
24Lee LA, Roberts CM, Frank MB, McCubbin VR, Reichlin M. The autoantibody response to Ro/SSA in cutaneous lupus erythematosus. Arch Dermatol 1994;130:1262-8.
25Morais SA, Isenberg DA. A study of the influence of ethnicity on serology and clinical features in lupus. Lupus 2017;26:17-26.
26Franceschini F, Cretti L, Quinzanini M, Lodi Rizzini F, Cattaneo R. Deforming arthropathy of the hands in systemic lupus erythematosus is associated with antibodies to SSA/Ro and to SSB/La. Lupus 1994;3:419-22.
27Choe J-Y, Lee S-S, Kwak SG, Kim S-K. Anti-Sm Antibody, Damage Index, and Corticosteroid Use Are Associated with Cardiac Involvement in Systemic Lupus Erythematosus: Data from a Prospective Registry Study. J Korean Med Sci 2020;35:e139.
28Ryu S, Fu W, Petri MA. Associates and predictors of pleurisy or pericarditis in SLE. Lupus Sci Med 2017;4:e000221.
29Artim-Esen B, Çene E, Şahinkaya Y, et al. Cluster analysis of autoantibodies in 852 patients with systemic lupus erythematosus from a single center. J Rheumatol 2014;41:1304-10.
Article is only available in PDF format. Show PDF
2024 ©️ Galenos Publishing House